Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Hall Website

Matthew D. Hall, Ph.D.

Selected Publications

1)  Pouliot LM, Shen DW, Suzuki T, Hall MD, Gottesman MM.
Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.
Exp. Cell Res. 319: 566-74, 2013.
2)  Shen DW, Pouliot LM, Hall MD, Gottesman MM.
Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.
Pharmacol. Rev. 64: 706-21, 2012.
3)  Pouliot LM, Chen YC, Bai J, Guha R, Martin SE, Gottesman MM, Hall MD.
Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.
Cancer Res. 72: 5945-55, 2012.
4)  Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM.
Collateral sensitivity as a strategy against cancer multidrug resistance.
Drug Resist. Updat. 15: 98-105, 2012.
5)  Hall MD, Daly HL, Zhang JZ, Zhang M, Alderden RA, Pursche D, Foran GJ, Hambley TW.
Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
Metallomics. 4: 568-75, 2012.
6)  Shen DW, Pouliot LM, Gillet JP, Ma W, Johnson AC, Hall MD, Gottesman MM.
The transcription factor GCF2 is an upstream repressor of the small GTPAse RhoA, regulating membrane protein trafficking, sensitivity to doxorubicin, and resistance to cisplatin.
Mol. Pharm. 9: 1822-33, 2012.
7)  Hall MD, Pike VW.
Avoiding barriers to PET radioligand development: cellular assays of brain efflux transporters.
J. Nucl. Med. 52: 338-40, 2011.
8)  Goldsborough AS, Handley MD, Dulcey AE, Pluchino KM, Kannan P, Brimacombe KR, Hall MD, Griffiths G, Gottesman MM.
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
J. Med. Chem. 54: 4987-97, 2011.
9)  Kannan P, Brimacombe KR, Kreisl WC, Liow JS, Zoghbi SS, Telu S, Zhang Y, Pike VW, Halldin C, Gottesman MM, Innis RB, Hall MD.
Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET.
Proc. Natl. Acad. Sci. U.S.A. 108: 2593-8, 2011.
10)  Hall MD, Brimacombe KR, Varonka MS, Pluchino KM, Monda JK, Li J, Walsh MJ, Boxer MB, Warren TH, Fales HM, Gottesman MM.
Synthesis and structure-activity evaluation of isatin-ß-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein.
J. Med. Chem. 54: 5878-89, 2011.
11)  Kannan P, Telu S, Shukla S, Ambudkar SV, Pike VW, Halldin C, Gottesman MM, Innis RB, Hall MD.
The "Specific" P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2).
ACS Chem Neurosci. 2: 82-9, 2011.
12)  Kannan P, Brimacombe KR, Zoghbi SS, Liow JS, Morse C, Taku AK, Pike VW, Halldin C, Innis RB, Gottesman MM, Hall MD.
N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier.
Drug Metab. Dispos. 38: 917-22, 2010.
13)  Brimacombe KR, Hall MD, Auld DS, Inglese J, Austin CP, Gottesman MM, Fung KL.
A dual-fluorescence high-throughput cell line system for probing multidrug resistance.
Assay Drug Dev Technol. 7: 233-49, 2009.
14)  Türk D, Hall MD, Chu BF, Ludwig JA, Fales HM, Gottesman MM, Szakács G.
Identification of compounds selectively killing multidrug-resistant cancer cells.
Cancer Res. 69: 8293-301, 2009.
15)  Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, Hall MD.
Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications.
Clin. Pharmacol. Ther. 86: 368-77, 2009.
16)  Hall MD, Handley MD, Gottesman MM.
Is resistance useless? Multidrug resistance and collateral sensitivity.
Trends Pharmacol. Sci. 30: 546-56, 2009.
17)  Hall MD, Salam NK, Hellawell JL, Fales HM, Kensler CB, Ludwig JA, Szakács G, Hibbs DE, Gottesman MM.
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
J. Med. Chem. 52: 3191-204, 2009.
18)  Davies MS, Hall MD, Berners-Price SJ, Hambley TW.
[1H, 15N] heteronuclear single quantum coherence NMR study of the mechanism of aquation of platinum(IV) ammine complexes.
Inorganic chemistry. 47: 7673-80, 2008.
19)  Namiki T, Valencia JC, Hall MD, Hearing VJ.
A novel approach to enhance antibody sensitivity and specificity by peptide cross-linking.
Anal. Biochem. 383: 265-9, 2008.
20)  Sarin H, Kanevsky AS, Wu H, Brimacombe KR, Fung SH, Sousa AA, Auh S, Wilson CM, Sharma K, Aronova MA, Leapman RD, Griffiths GL, Hall MD.
Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells.
J Transl Med. 6: 80, 2008.
21)  Okabe M, Szakács G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, Gottesman MM.
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters.
Mol. Cancer Ther. 7: 3081-91, 2008.
22)  Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM.
The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.
Annu. Rev. Pharmacol. Toxicol. 48: 495-535, 2008.
23)  Hall MD, Mellor HR, Callaghan R, Hambley TW.
Basis for design and development of platinum(IV) anticancer complexes.
J. Med. Chem. 50: 3403-11, 2007.
24)  Hall MD, Failes TW, Yamamoto N, Hambley TW.
Bioreductive activation and drug chaperoning in cobalt pharmaceuticals.
Dalton transactions (Cambridge, England : 2003). 3983-90, 2007.
25)  Oldfield SP, Hall MD, Platts JA.
Calculation of lipophilicity of a large, diverse dataset of anticancer platinum complexes and the relation to cellular uptake.
J. Med. Chem. 50: 5227-37, 2007.
26)  Alderden RA, Mellor HR, Modok S, Hall MD, Sutton SR, Newville MG, Callaghan R, Hambley TW.
Elemental tomography of cancer-cell spheroids reveals incomplete uptake of both platinum(II) and platinum(IV) complexes.
J. Am. Chem. Soc. 129: 13400-1, 2007.
27)  Wu CP, Shukla S, Calcagno AM, Hall MD, Gottesman MM, Ambudkar SV.
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.
Mol. Cancer Ther. 6: 3287-96, 2007.
28)  Modok S, Scott R, Alderden RA, Hall MD, Mellor HR, Bohic S, Roose T, Hambley TW, Callaghan R.
Transport kinetics of four- and six-coordinate platinum compounds in the multicell layer tumour model.
Br. J. Cancer. 97: 194-200, 2007.
29)  Hall MD, Alderden RA, Zhang M, Beale PJ, Cai Z, Lai B, Stampfl AP, Hambley TW.
The fate of platinum(II) and platinum(IV) anti-cancer agents in cancer cells and tumours.
J. Struct. Biol. 155: 38-44, 2006.
30)  Bonnitcha PD, Hall MD, Underwood CK, Foran GJ, Zhang M, Beale PJ, Hambley TW.
XANES investigation of the Co oxidation state in solution and in cancer cells treated with Co(III) complexes.
J. Inorg. Biochem. 100: 963-71, 2006.
31)  Culotta VC, Yang M, Hall MD.
Manganese transport and trafficking: lessons learned from Saccharomyces cerevisiae.
Eukaryotic Cell. 4: 1159-65, 2005.
32)  Mellor HR, Snelling S, Hall MD, Modok S, Jaffar M, Hambley TW, Callaghan R.
The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes.
Biochem. Pharmacol. 70: 1137-46, 2005.
33)  Hall MD, Martin C, Ferguson DJ, Phillips RM, Hambley TW, Callaghan R.
Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models.
Biochem. Pharmacol. 67: 17-30, 2004.
34)  Hall MD, Dolman RC, Hambley TW.
Platinum(IV) anticancer complexes.
Metal ions in biological systems. 42: 297-322, 2004.
35)  Hall MD, Amjadi S, Zhang M, Beale PJ, Hambley TW.
The mechanism of action of platinum(IV) complexes in ovarian cancer cell lines.
J. Inorg. Biochem. 98: 1614-24, 2004.
36)  Hall MD, Dillon CT, Zhang M, Beale P, Cai Z, Lai B, Stampfl AP, Hambley TW.
The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells.
J. Biol. Inorg. Chem. 8: 726-32, 2003.
37)  Hall MD, Foran GJ, Zhang M, Beale PJ, Hambley TW.
XANES determination of the platinum oxidation state distribution in cancer cells treated with platinum(IV) anticancer agents.
J. Am. Chem. Soc. 125: 7524-5, 2003.
38)  Hall MD, Failes TW, Hibbs DE, Hambley TW.
Structural investigations of palladium(II) and platinum(II) complexes of salicylhydroxamic acid.
Inorganic chemistry. 41: 1223-8, 2002.
39)  Platts JA, Hibbs DE, Hambley TW, Hall MD.
Calculation of the hydrophobicity of platinum drugs.
J. Med. Chem. 44: 472-4, 2001.
Click Here to View Collapsed Bibliography.

This page was last updated on 3/19/2013.